Praluent Approval History
FDA Approved: Yes (First approved July 24, 2015)
Brand name: Praluent
Generic name: alirocumab
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: High Cholesterol, High Cholesterol, Familial Heterozygous
Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody indicated:
- as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol LDL-C.
- to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Development History and FDA Approval Process for Praluent
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.